Triple Therapy under Real Life Conditions: Telaprevir (TVR) and Boceprevir (BOC) in Combination with Peginterferon alfa-2a plus Ribavirin (P/R) in Treatment Experienced Patients Infected with Chronic Hepatitis C, Genotype 1. The PAN Study . . . vorgestellt anlässlich der Digestive Disease Week 2013 (DDW) in Orlando (USA).
